


New and Novel Tools For Cancer Research




P5091

P5091

Selective inhibitor of the ubiquitin-specific protease USP7 ($IC_{50}=4.2 \mu M$)^{1,2}. Induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance¹. Displays antiangiogenesis activity *in vivo*².

10-1422

5 mg , 25 mg




ML-239

ML-239

Cancer stem cells (CSC) are resistant to standard cancer treatments. ML-239 was found to be selectively toxic to human breast epithelial cells transdifferentiated to a mesenchymal phenotype ($IC_{50}=1.2 \mu M$)³. Although its direct target has not yet been identified ML-239 is an important tool for research in selective killing of CSCs.

10-1417

5 mg , 25 mg




Dynasore

Manzamine A

Manzamine A, a marine sponge alkaloid, inhibits vacuolar ATPases⁴. At $10 \mu M$, it induces autophagy markers in pancreatic cancer cells suggesting that it inhibits autophagosome turnover. As autophagy is essential for pancreatic tumor growth, manzamine may be a potential pancreatic cancer therapeutic.

10-2675

1 mg , 5 mg



KY-02111

680C91

A potent and selective inhibitor of tryptophan 2,3-dioxygenase (TDO) ($K_i=42 \text{ nM}$)^{5,6}. Displays no activity against indoleamine 2,3-dioxygenase, MAO-A and B and does not affect serotonin uptake. TDO inhibition by 680C91 in glioma cells blocked the release of kynurenine, an endogenous tumor promoting AHR ligand⁷.

10-1443

5 mg , 25 mg

References

1. D Chauhan, *et al.* 2012 *Cancer Cell* **22** 345
2. J Weinstock, *et al.* 2012 *ACS Med. Chem. Lett.* **3** 789
3. LC Carmody, *et al.* 2012 *J. Biomol. Screening* **17** 1204
4. G Kallifatidis, *et al.* 2013 *Mar. Drugs* **11** 3500
5. R Schwarcz and R Pellicciari 2002 *J. Pharmacol. Exp. Therap.* **303** 1
6. M Salter *et al.* 1995 *Biochem. Pharmacol.* **49** 1435H
7. CA Opitz *et al.* 2011 *Nature* **478** 198
8. Yamada, *et al.* 2009 *Biochem. Biophys. Res. Commun.* **390** 1142
9. I Minami, *et al.* 2012 *Cell Rep.* **2** 1448

Dynasore

Dynasore, a highly selective dynamin inhibitor (GTPase activity), suppresses lamellipodia formation and cancer cell invasion by destabilizing actin filaments⁸.

10-1427

5 mg , 25 mg

KY-02111

Inhibits Wnt signaling but in a manner that is distinct from previously described Wnt inhibitors⁹. Promotes cardiac differentiation of human pluripotent stem cells.

10-1437

5 mg , 25 mg